CoChat

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

Open access
Cheng, Dihe, Yang, Shuo, Zhao, Xue, Wang, Guixia · 2022 · Drug Design, Development and Therapy

The DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.

Abstract

Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s348055

Cites

231 of 231 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Insulin and GLP-1-dependent intracellular signal transduction pathways are similar. Insulin binds to the insulin receptor and further activates the PI3K/Akt and MAPK pathways signaling. PI3K/Akt pathway modulates some cellular processes, such as cell survival, proliferation, apoptosis, protein synthesis, inflammation, ER stress, mitochondrial function, autophagy, synaptic strength in neurodegenerative disorders. MAPK pathway regulates various cellular activities including synaptic plasticity and neuroinflammation. When GLP-1 binds to the GLP-1 receptor, adenosine cyclase is activated and intracellular cAMP increases, thereby activating PKA and PI3K. The downstream pathways are mainly the PI3K and MAPK pathways; hence, the GLP-1 signaling and insulin signaling pathways are similar and partially overlapping.
Figure 1 Insulin and GLP-1-dependent intracellular signal transduction pathways are similar. Insulin binds to the insulin receptor and further activates the PI3K/Akt and MAPK pathways signaling. PI3K/Akt pathway modulates some cellular processes, such as cell survival, proliferation, apoptosis, protein synthesis, inflammation, ER stress, mitochondrial function, autophagy, synaptic strength in neurodegenerative disorders. MAPK pathway regulates various cellular activities including synaptic plasticity and neuroinflammation. When GLP-1 binds to the GLP-1 receptor, adenosine cyclase is activated and intracellular cAMP increases, thereby activating PKA and PI3K. The downstream pathways are mainly the PI3K and MAPK pathways; hence, the GLP-1 signaling and insulin signaling pathways are similar and partially overlapping.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Show all 231 references

Research works printed but not linked: 3

  1. Youssef, 2009, West Indian Med J, 58, 410
  2. Qi, 2017, Am J Transl Res, 9, 247
  3. Egefjord, 2012, Dan Med J, 59, A4519

Cited by

Metadata

Authors
Cheng, D., Yang, S., Zhao, X., & Wang, G.
Affiliations
First Hospital of Jilin University (CN)
Corresponding author
Wang, Guixia
Venue
Drug Design, Development and Therapy
Published
2022-03
Volume
Volume 16
Pages
665-684
ISSN
1177-8881 (ISSN-L)
OpenAlex
W4221041575
Cited by
84
References
229
Citations by year
2026: 21 · 2025: 27 · 2024: 13 · 2023: 18 · 2022: 5
FWCI
2.17
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • People's Government of Jilin Province
  • Jilin University
  • First Hospital of Jilin University
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
GLP-1 receptor agonists, neurodegenerative diseases, diabetes mellitus, Alzheimer's disease, Parkinson's disease, neuroprotection, type 2 diabetes, type 1 diabetes, obesity, cognitive impairment, molecular mechanisms
MeSH terms
Glucagon-Like Peptide-1 Receptor, Aged, Diabetes Mellitus, Type 2, Humans, Insulin, Neurodegenerative Diseases, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.